Physician profile
David Schick
NPI 1013234343
$21,418.65
in general payments reported to CMS, 2019-2025
53 companies · $4,628 in 2025
The $4,628 reported for 2025 was more than what 84% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,696 · 2020: $1,741 · 2021: $2,584 · 2022: $3,018 · 2023: $3,134 · 2024: $3,617 · 2025: $4,628.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $18.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,360.77 |
| Education | $18.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,704.85 | 2021-2025 | Qulipta, Ubrelvy |
| Amneal Pharmaceuticals LLC | $1,926.24 | 2019-2025 | Crexont, Rytary, Ongentys |
| Acadia Pharmaceuticals INC | $1,761.17 | 2019-2025 | Nuplazid, Daybue |
| Biogen, INC. | $1,475.63 | 2019-2025 | Vumerity, Tysabri, Leqembi |
| Lilly USA, LLC | $1,468.80 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Emd Serono, INC. | $805.69 | 2019-2025 | Mavenclad, Mavenclad |
| Pfizer INC. | $761.15 | 2019-2025 | |
| Ucb, INC. | $746.95 | 2019-2025 | Rystiggo, Briviact, Nayzilam |
| Neurocrine Biosciences, INC. | $702.55 | 2020-2025 | Ingrezza, Ongentys |
| Celgene Corporation | $582.62 | 2021-2025 | Zeposia |
| Amgen INC. | $513.97 | 2019-2025 | Uplizna |
| Teva Pharmaceuticals USA, INC. | $503.77 | 2019-2025 | Austedo Xr, Ajovy, Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $498.83 | 2020-2025 | Zeposia |
| Genzyme Corporation | $474.47 | 2019-2022 | |
| Eisai INC. | $471.52 | 2023-2025 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Schick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.